Shengping Li
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis 2
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research 6
- Inflammatory Biomarkers in Disease Prognosis 3
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 15
-
- Microbial Inactivation Methods 3
-
- Gallbladder and Bile Duct Disorders 7
-
- Hepatitis B Virus Studies 3
- Liver Disease Diagnosis and Treatment 2
- Cited by
- HepatologyOncologyCancer Research
- Journals
- Journal of Biological Chemistry (1 paper)Frontiers in Immunology (2 papers)Cancer Letters (1 paper)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Shengping Li
25 papers receiving 558 citations
Peers
Comparison fields: 5 of 57
- Hepatology 101
- Oncology 278
- Cancer Research 105
- Surgery 239
- Biotechnology 35
Countries citing papers authored by Shengping Li
This map shows the geographic impact of Shengping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengping Li more than expected).
Fields of papers citing papers by Shengping Li
This network shows the impact of papers produced by Shengping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengping Li. The network helps show where Shengping Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shengping Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 0 | |
| 4 | 2022 | 8 | |
| 5 | 2021 | 10 | |
| 6 | 2021 | 0 | |
| 7 | 2020 | 12 | |
| 8 | 2020 | 11 | |
| 9 | 2019 | 4 | |
| 10 | 2019 | 7 | |
| 11 | 2019 | 16 | |
| 12 | 2018 | 16 | |
| 13 | 2018 | 36 | |
| 14 | 2018 | 28 | |
| 15 | 2018 | 32 | |
| 16 | 2017 | 19 | |
| 17 | 2016 | 10 | |
| 18 | 2016 | 5 | |
| 19 | 2014 | 86 | |
| 20 | 2014 | 41 |
About Shengping Li
Shengping Li is a scholar working on Hepatology, Oncology and Surgery, having authored 28 papers that have together received 565 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Gallbladder and Bile Duct Disorders (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Microbial Inactivation Methods (3 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), Hepatitis B Virus Studies (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Liver Disease Diagnosis and Treatment (2 papers). The work is most often cited by research in Hepatology (101 citations), Oncology (278 citations) and Cancer Research (105 citations). Shengping Li has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Yize Mao, Guo‐He Lin, Xiang‐Ming Lao, Xiaojun Lin, Jianlin Chen, Zeyu Shuang, Chaobin He, Xin Huang, Jun Wang and Yongcheng Liu. Their work appears in journals such as Journal of Biological Chemistry, Frontiers in Immunology and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.